This phase II trial tests how well an abbreviated course of accelerated partial breast irradiation (APBI) using brachytherapy works in controlling disease in patients who have undergone lumpectomy for breast cancer. Radiation therapy uses a type of energy to kill cancer cells and shrink tumors. It destroys cells in the area being treated by damaging their genetic matter. This makes it impossible for these cells to keep growing and dividing. Radiation damages both tumor cells and normal cells, but most normal cells can recover and function properly. Brachytherapy is a type of internal radiation therapy. It uses tubes called catheters to deliver radiation inside the breast in the space created by the lumpectomy. This puts the radiation close to any remaining tumor cells next to the space where the tumor was removed. It does not treat the whole breast. Radiation therapy is often given after lumpectomy to improve control of the cancer within the breast, and is usually given over 5 to 8 days. Giving APBI using brachytherapy over 2 days instead may work better in treating patients with breast cancer who have undergone lumpectomy.
Additional locations may be listed on ClinicalTrials.gov for NCT06185205.
Locations matching your search criteria
United States
Virginia
Richmond
VCU Massey Comprehensive Cancer CenterStatus: Active
Contact: Bridget A Quinn
Phone: 804-828-7232
PRIMARY OBJECTIVE:
I. Assess and compare the toxicity (at 1 and 3 years) of a 1.5-day APBI treatment course as compared to National Surgical Adjuvant Breast and Bowel Project (NSABP)/Radiation Therapy Oncology Group (RTOG) B39/0413 and the Virginia Commonwealth University (VCU) retrospective cohort.
SECONDARY OBJECTIVES:
I. Assess the rate of excellent or good cosmesis at 1, 3, and 5 years after a 1.5-day course of APBI.
II. Determine the 3- and 5-year actuarial local control rate of breast cancer when treated with a 1.5-day course of APBI.
III. Assess cumulative treatment-related breast toxicities for up to 5 years after a 1.5-day course of APBI.
IV. Conduct detailed evaluation of the severity of punctate scarring at 5 weeks, 6 months, and yearly through 5 years after a 1.5-day course of APBI.
OUTLINE:
Patients undergo catheter placement and then undergo APBI brachytherapy for a total of 3 fractions over 48 hours. Patients also undergo computed tomography (CT) on trial and undergo collection of blood samples and mammography at screening and during follow up. Patients may optionally undergo magnetic resonance imaging (MRI) at screening and follow up.
After completion of study treatment, patients are followed up at 5 weeks and 6 months, and then every 6 months for up to 5 years.
Lead OrganizationVCU Massey Comprehensive Cancer Center
Principal InvestigatorBridget A Quinn